The Global Transthyretin Amyloidosis Treatment Market was valued at USD 9.5 billion in 2025 and is estimated to grow at a CAGR of 7.8% to reach USD 23.7 billion by 2035.
The market is witnessing expansion driven by increasing identification of hereditary and wild-type transthyretin amyloidosis cases, growing awareness of rare cardiac and neurological conditions, and rising utilization of advanced disease-modifying therapies focused on transthyretin stabilization and gene silencing approaches. Improvements in diagnostic accuracy are playing a major role in strengthening market growth, as modern imaging and testing methods are enabling earlier and more reliable detection of disease progression. In parallel, greater physician awareness and the adoption of structured diagnostic pathways are expanding the diagnosed patient pool across regions. The industry is also experiencing a structural shift from traditional supportive care toward targeted therapeutic interventions that address the underlying disease mechanism rather than only managing symptoms. Rising global epidemiological evidence continues to highlight a larger-than-expected disease burden, reinforcing the need for advanced treatment options and long-term management strategies.
The TTR stabilizers segment generated USD 6.4 billion in 2025. This leadership position is largely supported by widespread adoption of tafamidis-based therapies, particularly for both hereditary and wild-type transthyretin amyloid cardiomyopathy cases. Strong commercial performance is reinforced by the extensive use of therapies such as Pfizer’s Vyndaqel and Vyndamax, which were among the first FDA-approved treatments for transthyretin amyloid cardiomyopathy in 2019. Clinical evidence supporting improved survival outcomes and reduced hospitalization rates has further strengthened physician confidence and sustained demand for this drug class across healthcare systems.
The oral administration segment is projected to grow at a CAGR of 6.6% between 2026 and 2035. Oral therapies are preferred due to their ease of administration, improved patient adherence, and overall convenience in long-term treatment management. These advantages contribute to better compliance and more consistent therapeutic outcomes in chronic disease settings. Additionally, oral formulations are generally associated with improved safety and reduced risk of administration-related complications compared to alternative delivery methods. Continuous development of next-generation oral treatments targeting transthyretin amyloidosis is further expanding therapeutic options and enhancing patient quality of life.
North America Transthyretin Amyloidosis Treatment Market held a share of 60.1% in 2025. The region’s leadership is supported by high awareness of rare cardiac diseases, rapid adoption of advanced treatment approaches, and a strong presence of pharmaceutical innovators focused on transthyretin amyloidosis therapies. Well-established diagnostic infrastructure, including advanced imaging techniques and genetic testing capabilities, has significantly improved early detection rates, particularly for transthyretin amyloid cardiomyopathy. In addition, favorable reimbursement frameworks and expanding access to high-value orphan drugs, including tafamidis and RNA-based therapies, continue to reinforce market growth across the region.
Key companies operating in the Global Transthyretin Amyloidosis Treatment Market include Pfizer, AstraZeneca, Alnylam Pharmaceuticals, Ionis Pharmaceuticals, BridgeBio Pharma, Intellia Therapeutics, Neurimmune, and Prothena Corporation. Companies in the transthyretin amyloidosis treatment market are increasingly focusing on expanding their clinical research pipelines to develop next-generation disease-modifying therapies that go beyond symptom management. A major strategy involves advancing RNA interference and gene silencing technologies to directly target transthyretin protein production. Firms are also strengthening partnerships with research institutions and biotech innovators to accelerate drug discovery and improve clinical trial success rates. Another key approach includes expanding regulatory approvals across multiple regions to widen patient access and improve commercial reach. Companies are investing heavily in real-world evidence generation to demonstrate long-term treatment benefits and support reimbursement discussions. Strategic emphasis is also placed on developing oral and patient-friendly formulations to enhance adherence in chronic therapy settings.
This product will be delivered within 2-4 business days.
The market is witnessing expansion driven by increasing identification of hereditary and wild-type transthyretin amyloidosis cases, growing awareness of rare cardiac and neurological conditions, and rising utilization of advanced disease-modifying therapies focused on transthyretin stabilization and gene silencing approaches. Improvements in diagnostic accuracy are playing a major role in strengthening market growth, as modern imaging and testing methods are enabling earlier and more reliable detection of disease progression. In parallel, greater physician awareness and the adoption of structured diagnostic pathways are expanding the diagnosed patient pool across regions. The industry is also experiencing a structural shift from traditional supportive care toward targeted therapeutic interventions that address the underlying disease mechanism rather than only managing symptoms. Rising global epidemiological evidence continues to highlight a larger-than-expected disease burden, reinforcing the need for advanced treatment options and long-term management strategies.
The TTR stabilizers segment generated USD 6.4 billion in 2025. This leadership position is largely supported by widespread adoption of tafamidis-based therapies, particularly for both hereditary and wild-type transthyretin amyloid cardiomyopathy cases. Strong commercial performance is reinforced by the extensive use of therapies such as Pfizer’s Vyndaqel and Vyndamax, which were among the first FDA-approved treatments for transthyretin amyloid cardiomyopathy in 2019. Clinical evidence supporting improved survival outcomes and reduced hospitalization rates has further strengthened physician confidence and sustained demand for this drug class across healthcare systems.
The oral administration segment is projected to grow at a CAGR of 6.6% between 2026 and 2035. Oral therapies are preferred due to their ease of administration, improved patient adherence, and overall convenience in long-term treatment management. These advantages contribute to better compliance and more consistent therapeutic outcomes in chronic disease settings. Additionally, oral formulations are generally associated with improved safety and reduced risk of administration-related complications compared to alternative delivery methods. Continuous development of next-generation oral treatments targeting transthyretin amyloidosis is further expanding therapeutic options and enhancing patient quality of life.
North America Transthyretin Amyloidosis Treatment Market held a share of 60.1% in 2025. The region’s leadership is supported by high awareness of rare cardiac diseases, rapid adoption of advanced treatment approaches, and a strong presence of pharmaceutical innovators focused on transthyretin amyloidosis therapies. Well-established diagnostic infrastructure, including advanced imaging techniques and genetic testing capabilities, has significantly improved early detection rates, particularly for transthyretin amyloid cardiomyopathy. In addition, favorable reimbursement frameworks and expanding access to high-value orphan drugs, including tafamidis and RNA-based therapies, continue to reinforce market growth across the region.
Key companies operating in the Global Transthyretin Amyloidosis Treatment Market include Pfizer, AstraZeneca, Alnylam Pharmaceuticals, Ionis Pharmaceuticals, BridgeBio Pharma, Intellia Therapeutics, Neurimmune, and Prothena Corporation. Companies in the transthyretin amyloidosis treatment market are increasingly focusing on expanding their clinical research pipelines to develop next-generation disease-modifying therapies that go beyond symptom management. A major strategy involves advancing RNA interference and gene silencing technologies to directly target transthyretin protein production. Firms are also strengthening partnerships with research institutions and biotech innovators to accelerate drug discovery and improve clinical trial success rates. Another key approach includes expanding regulatory approvals across multiple regions to widen patient access and improve commercial reach. Companies are investing heavily in real-world evidence generation to demonstrate long-term treatment benefits and support reimbursement discussions. Strategic emphasis is also placed on developing oral and patient-friendly formulations to enhance adherence in chronic therapy settings.
Comprehensive Market Analysis and Forecast
- Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape
- Competitive landscape with Porter’s Five Forces and PESTEL analysis
- Market size, segmentation, and regional forecasts
- In-depth company profiles, business strategies, financial insights, and SWOT analysis
This product will be delivered within 2-4 business days.
Table of Contents
Chapter 1 Methodology and Scope
Chapter 2 Executive Summary
Chapter 3 Industry Insights
Chapter 4 Competitive Landscape, 2025
Chapter 5 Market Estimates and Forecast, by Treatment Type, 2022-2035 ($ Mn)
Chapter 6 Market Estimates and Forecast, by Disease Type, 2022-2035 ($ Mn)
Chapter 7 Market Estimates and Forecast, by Route of Administration, 2022-2035 ($ Mn)
Chapter 8 Market Estimates and Forecast, by Distribution Channel, 2022-2035 ($ Mn)
Chapter 9 Market Estimates and Forecast, by Region, 2022-2035 ($ Mn)
Chapter 10 Company Profiles
Companies Mentioned
The companies profiled in this Transthyretin Amyloidosis Treatment market report include:- Alnylam Pharmaceuticals
- AstraZeneca
- BridgeBio Pharma
- Ionis Pharmaceuticals
- Intellia Therapeutics
- Neurimmune
- Prothena Corporation
- Pfizer
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 136 |
| Published | May 2026 |
| Forecast Period | 2025 - 2036 |
| Estimated Market Value ( USD | $ 9.5 Billion |
| Forecasted Market Value ( USD | $ 23.7 Billion |
| Compound Annual Growth Rate | 7.8% |
| Regions Covered | Global |
| No. of Companies Mentioned | 9 |
